US Broker Ratings

Centene Corporation (CNC) Stock Analysis: Evaluating a 13.95% Upside Potential in the Healthcare Sector

Centene Corporation (NYSE: CNC) stands as a formidable player in the healthcare plans industry, offering managed care services across diverse segments such as Medicaid, Medicare, and Commercial. With a market..

Koninklijke Philips N.V. (PHG) Stock Analysis: A 34.32% Upside Potential in the Healthcare Sector

Investors eyeing opportunities in the healthcare sector may want to take a closer look at Koninklijke Philips N.V. (NYSE: PHG), a leading name in the medical devices industry. With a..

Pfizer, Inc. (PFE) Stock Analysis: A Healthcare Giant with a Robust 6.19% Dividend Yield and Strategic Collaborations

Pfizer Inc. (NYSE: PFE), a cornerstone in the healthcare sector, continues to capture investor attention with its impressive dividend yield and strategic partnerships. As a leading player in the drug..

Royalty Pharma plc (RPRX) Stock Analysis: Exploring a 13.93% Potential Upside

Royalty Pharma plc (NASDAQ: RPRX) stands out in the biopharmaceutical sector as a unique entity specializing in the acquisition of royalties and funding innovation. With a market capitalization of $33.03..

argenx SE (ARGX) Stock Analysis: Biotechnology Leader with 28.40% Potential Upside

argenx SE (NASDAQ: ARGX), a prominent player in the biotechnology sector, has captured investor attention with its robust pipeline and impressive market cap of $57.51 billion. Based in the Netherlands,..

Labcorp Holdings Inc. (LH) Stock Analysis: Exploring Growth Potential with a Promising 11.77% Upside

Labcorp Holdings Inc. (NYSE: LH), a leader in the healthcare sector, specifically within diagnostics and research, presents an intriguing investment opportunity. With a market capitalization of $25.02 billion, Labcorp is..

Novo Nordisk A/S (NVO): Unpacking the 23% Upside Potential in Healthcare Giant’s Stock

Novo Nordisk A/S (NVO), a prominent player in the healthcare sector, stands at the forefront of innovation in drug manufacturing, particularly in the treatment of diabetes, obesity, and rare diseases...

Becton, Dickinson and Company (BDX) Stock Analysis: Evaluating Growth Potential and Analyst Ratings for This Healthcare Giant

Becton, Dickinson and Company (NYSE: BDX) stands as a pivotal player in the healthcare industry, with a robust market capitalization of $48.16 billion. Founded in 1897, this Franklin Lakes, New..

Eli Lilly and Company (LLY) Stock Analysis: Exploring a 16.27% Upside with Strong Revenue Growth

Eli Lilly and Company (NYSE: LLY), a titan in the healthcare sector and a key player in the general drug manufacturing industry, has been making waves in the investment community..

Cigna Group (CI) Stock Analysis: Unveiling a 26.53% Upside Potential

For individual investors eyeing opportunities in the healthcare sector, The Cigna Group (NYSE: CI) presents an intriguing proposition. With its robust market cap of $71.48 billion, Cigna stands as a..

Alcon Inc. (ALC) Stock Analysis: Eye-Catching 32.45% Upside Potential for Investors

Alcon Inc. (NYSE: ALC) is a prominent player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $30.82 billion, this Swiss-based company..

Takeda Pharmaceutical Company L (TAK) Stock Analysis: Exploring a 23% Upside Potential

Takeda Pharmaceutical Company Limited (NYSE: TAK), a stalwart in the healthcare sector, is capturing investor attention with its substantial market capitalization of $57.06 billion and a promising analyst outlook indicating..

Cencora, Inc. (COR) Stock Analysis: Exploring a 19.48% Potential Upside in the Healthcare Distribution Arena

Cencora, Inc. (NYSE: COR), a stalwart in the healthcare sector, particularly in medical distribution, is capturing investor attention with a compelling 19.48% potential upside based on current analyst targets. With..

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unveiling a 68.91% Potential Upside for Investors

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a pioneering entity in the biotechnology sector, is renowned for its innovative approach to developing therapeutics based on ribonucleic acid interference (RNAi). With a market..

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 35% Potential Upside and Robust Buy Ratings

AstraZeneca PLC (AZN), a leading player in the healthcare sector, particularly within the general drug manufacturing industry, is capturing investor attention with a compelling mix of strategic growth, robust financials,..

Stryker Corporation (SYK) Stock Analysis: Exploring a 33.54% Potential Upside Amid Robust Revenue Growth

Stryker Corporation (NYSE: SYK), a prominent player in the medical devices industry, is drawing considerable attention from investors, thanks to its promising growth prospects and a potential upside of 33.54%..

Elevance Health, Inc. (ELV) Stock Analysis: Unpacking a 16.81% Potential Upside Opportunity

Investors seeking opportunities in the healthcare sector may find Elevance Health, Inc. (NYSE: ELV) an intriguing prospect. With a market capitalization of $83.8 billion, this Indianapolis-based healthcare giant operates across..

Vertex Pharmaceuticals (VRTX) Stock Analysis: Strong Buy Ratings and Promising Growth Potential

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stands as a formidable player in the biotechnology sector, renowned for its innovative approaches to tackling challenging diseases. With a market capitalization of $127.85 billion,..

Danaher Corporation (DHR) Stock Analysis: Strong Buy Ratings and a 10.4% Upside Potential

Danaher Corporation (NYSE: DHR), a stalwart in the healthcare sector, has captured investor attention with its robust market presence and promising growth potential. With a market capitalization of $150.48 billion,..

Boston Scientific Corporation (BSX) Stock Analysis: Unpacking a 42.71% Potential Upside

Boston Scientific Corporation (NYSE: BSX), a titan in the healthcare sector specializing in medical devices, offers compelling prospects for investors, underscored by a notable potential upside of 42.71%. The company,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds